Language Considerations When Expanding Clinical Trials Internationally 

When a sponsor decides to add countries to a trial, the planning conversation usually starts with sites, timelines and budget. Language tends to arrive later, once the protocol is settled and somebody notices that the consent form now has to exist in every language of every country on the list. 

Leaving it until then costs money, and the timing decides whether participants understand what they’re agreeing to, whether an ethics committee can review the paperwork without sending back a pile of questions, whether the submission goes in on schedule, and whether answers collected in one country mean the same thing as answers collected in another. 

Below, we look at where language shows up under the EU Clinical Trials Regulation (EU CTR 536/2014) and its submission portal, the Clinical Trials Information System (CTIS), and how to get it onto the plan early. 

Where Language Shows Up in a Trial 

Once a trial crosses a border, the paperwork multiplies. Site and investigator materials go out during feasibility. The submission carries country-specific documents, consent forms and recruitment material, and reviewers send questions that need answers quickly. After enrollment starts, participants fill in questionnaires and diaries, and at the end there’s a results summary written for the public. 

Most of those carry a deadline set by a regulator, an ethics committee or a site, and a late translation won’t move it. Rushed work is also when terminology starts to drift between documents that were supposed to say the same thing. 

What the EU CTR and CTIS Say About Language 

The Clinical Trials Regulation moved EU submissions into a single portal, CTIS, but it left language with the individual countries. Article 26 says the language of the application dossier, or parts of it, is determined by the member state concerned, and it asks member states to consider accepting a commonly understood language in the medical field for documents that are not addressed to the trial subject (Regulation (EU) No 536/2014). The regulation began to apply on Jan. 31, 2022, and since Jan. 31, 2025, every clinical trial in the EU and EEA has had to follow it and use CTIS. So you file one application through one portal and still meet each country’s own language rules. 

The dossier itself comes in two parts. Part I covers the science and the medicinal product and is assessed jointly, led by a reporting member state. Part II is assessed by each country on its own and holds the national documents. The European Commission’s Q&A shows how that plays out. Its Annex II says all member states accept just the English version of documents such as the investigator’s brochure, good manufacturing practice (GMP) compliance documentation and the investigational medicinal product dossier (IMPD) (EC Q&A, Annex II), though it also carries country notes: Hungary and the Czech Republic, for example, require a scientific summary of the protocol in the national language. For a multinational trial, patient-facing documents tied to the primary or secondary endpoints go into Part I in English and their translations are submitted in Part II, alongside recruitment material and subject information sheets. The Q&A is also clear that sponsors are responsible for the quality of the texts provided to subjects. 

Annex II is a starting point, and each country’s current rules still need checking. Our suggestion is to build a language matrix during planning: every document, every country, the language each one needs and the date it is due. 

Information Requests Leave Very Little Room for Translation Delays 

Once an application is in review, the clock gets tight. Under Article 6, the final Part I assessment report is due within 45 days of validation. If the reporting member state asks the sponsor for more information, that period can be extended by a maximum of 31 days, and the time the sponsor gets to respond cannot exceed 12 days. Miss that deadline, and the application is deemed to have lapsed in all member states concerned. Article 7 gives Part II a similar shape: 45 days for each member state’s assessment, a possible extension of up to 31 days, no more than 12 days for the sponsor to respond, and a further 19 days at most to complete the assessment, although a missed response there lapses the application only in that member state. 

Twelve days isn’t much for any response, and it’s less when the answer means changing a sentence in a consent form that exists in several languages, because the source text has to be revised, each translation updated and the results checked, all inside the same window. Here’s what helps. Approved terminology and translation memory mean a revised sentence is changed once and stays consistent wherever it appears. A language partner who already knows the study and has agreed turnaround times in advance is better placed to handle a 12-day window than one hearing about it for the first time. And tracked changes in the English source mean only the altered passages go back for translation. 

The timelines above come straight from the regulation text. CTIS operating guidance keeps evolving, so check current practice for each country. 

Informed Consent Has to Be Understood by the Person Signing It 

A consent form can be translated accurately and still fail the person holding it. The regulation requires consent information to be kept “comprehensive, concise, clear, relevant, and understandable to a layperson” (Article 29), and its recitals speak of information given in a language the potential participant easily understands. The Commission’s Q&A adds that patient-facing documents should reach participants in a language they understand, and the ICH Good Clinical Practice guideline adopted in January 2025 asks for consent materials that use simple language and avoid unnecessary volume and complexity. All three come back to the same point: participants need to understand what they’re told. 

Concepts like randomization or placebo can be difficult to express in everyday terms, and a literal rendering can look perfectly correct to a linguist while still confusing a patient. Reading level, sentence length, the way risks are phrased and even the formality of address all affect comprehension, and they differ from one language to the next. 

Most of the fix happens before translation starts. A plainly written English source makes every language version clearer, and it is far cheaper than repairing translations one at a time. Qualified linguists matter as well: the PRO Consortium stresses using qualified translators rather than people without proper training in translation (Eremenco et al., 2018), so a translator with clinical research experience, followed by an independent review, is the safer setup. For higher-risk populations or complex designs, test draft wording with people from the target language group before a committee does it for you. Settle early, with each site and ethics committee, how patients who don’t read the majority-language form will be informed. 

Amendments multiply the work. ICH E6(R3) says revised consent materials should receive ethics committee approval in advance of use, and the Commission’s Q&A says materials needed for re-consent are provided as Part II documents within a substantial modification. In a multilingual trial, every change therefore triggers translation, review and approval in each language, which is why version control across languages belongs in the plan from the first submission. 

Lay Summaries Are a Multilingual Deliverable Too 

Language planning doesn’t end when enrollment does. Within one year of the end of a trial in all member states concerned, and whatever the outcome, the sponsor has to submit a summary of results (Annex IV) and a summary written for laypersons (Annex V) to the EU database. If scientific reasons detailed in the protocol make that impossible, the summary goes in as soon as it is available and the protocol says when (Article 37(4)). That date drives the translation schedule, so the language plan should be built around it from the start. 

On language, the summary of results and the lay summary are treated differently. The Commission’s Q&A expects the summary of results itself to be submitted in English, with no translations required (EC Q&A, Chapter 6). For the lay summary, the Good Lay Summary Practice guidance (GLSP) notes that the regulation does not request translations, but it cites the EU expert group’s recommendation that, as a minimum, the lay summary be provided in the local official languages of the countries where the trial took place, matching the languages used in the patient information sheet (GLSP; expert group recommendations). GLSP calls availability in patients’ native language “an important element of fair access to information.” 

GLSP was adopted by the Commission’s Clinical Trials Expert Group in July 2021 and published that October. It asks for summaries that people with low to average health literacy can follow, accessible to young people from age 12 upwards and written in short words and sentences. The earlier expert group recommendations add that a summary should assume no prior knowledge of medical terminology and contain no promotional content. Annex V sets out the content, from trial identification and population through results and adverse reactions to where readers can find more information (Annex V). 

GLSP also gives practical advice on translation. It says translations should be made available “as soon as possible, ideally in parallel to the release of the source version,” and that thorough review before translation, a well-managed translation process and glossaries with pre-defined terminology all help. It recommends inviting patient experts during planning and, where possible, testing the master summary with members of the public who have no familiarity with clinical trials. Use the same terms in the lay summary that the consent form used, so a participant who reads both sees the same words for the same ideas. 

Linguistic Validation Keeps Questionnaire Data Comparable Across Languages 

Consent forms get read once. Questionnaires, diaries and other patient-reported outcome (PRO) instruments are often completed repeatedly, and the answers can become trial endpoints. Suppose an item means something slightly different to patients in Spain than it does to patients in Poland. The numbers from the two countries stop being comparable, even when both translations look fine on the page. 

Linguistic validation exists to prevent that. It goes beyond translation by testing the translated text with people from the target population, usually through cognitive interviews, to confirm that patients read each item the way its developers intended (Eremenco et al., 2018). The PRO Consortium’s process builds on the ISPOR task force’s earlier 10-step approach and runs to 12 steps. The core of it looks like this: 

  1. Preparation and forward translation, with at least two forward translations of the instrument. 
  2. Reconciliation, where the translations are merged into one version and the rationale is documented. 
  3. Back-translation and revision, where an independent back-translation, kept blind to the original, is compared with the source to check that meaning survived, and the text is revised where it did not. 
  4. International harmonization, where every language version is reviewed against the others and the original so that concepts stay equivalent across the study. 
  5. Proofreading and cognitive interviewing: remaining errors are corrected, then at least five patients per language and country, matched to the target population as far as practical, test the wording, and a final review confirms equivalence across languages. 

The ISPOR task force found that translation companies often used differing methods for similar tasks, which could increase variability between languages and potentially undermine the validity of research data. The PRO Consortium describes international harmonization as the step that helps ensure data from global trials can be safely aggregated, and it describes FDA guidance as stressing the comparability of measurement properties across all language versions of a PRO measure. 

Validation also takes time: patients have to be recruited and interviewed and the results reported back, in every language, and none of that can be squeezed in at the end. It belongs in the study timeline next to protocol finalization, and it is worth checking whether a validated translation of each instrument already exists before commissioning new work. 

Ethics Committee Readiness Depends on Local-Language Documents 

Most of what a country reviews in Part II, from subject information sheets and recruitment material to translated patient-facing documents, arrives in the local language (EC Q&A, paras 76 to 80). The people reviewing those documents, ethics committees among them, are reading the local-language versions, and the quality of those versions shapes how the review goes. 

A translation that is awkward, inconsistent with another document or hard to follow can prompt a question, and during Part II assessment a request for information leaves the sponsor no more than 12 days to respond. Clear, consistent local documents give reviewers less to query. Before submission, ask three things in every country: does the consent form say the same thing as the protocol, is the language suitable for the people who will read it, and are all versions current? On that last point, a revised consent form needs approval before it is used, so every language version has to track the latest approved text. 

Six Ways to Bring Language Into the Plan 

Multilingual planning works best when the team that decides which countries to enter takes it on from day one. Here’s where we’d begin. 

  1. Build the language matrix at feasibility: every document, every country, the language each reviewer requires and the date it is needed. It shows the real translation workload before commitments are made. 
  2. Write the source documents with translation in mind. Plain sentences, defined terms and stable wording in the protocol summary, consent form and lay summary template reduce errors in every language that follows. 
  3. Set terminology once. A shared glossary and translation memory keep the same term for the same idea across consent forms, questionnaires, site materials and the final lay summary. 
  4. Schedule linguistic validation alongside protocol finalization, check whether validated translations of each instrument already exist, and start new work early for the ones that do not. 
  5. Agree turnaround times for information requests and amendments before you need them, so a 12-day response window doesn’t turn into a scramble. 
  6. Keep a person at each end of the process. A qualified linguist or regulatory lead sets the context and the stakes; translation memory and, where it makes sense, AI-assisted tools carry the volume and speed; and a qualified reviewer checks the result before anything reaches a committee or a patient. For consent forms and patient-reported outcome instruments, that last human check is never optional. 

How BIG Can Help 

BIG translates the documents this post covers, including informed consent forms, lay summaries, ethics committee letters, case report forms and clinical outcome assessments, for sponsors, CROs and regulatory teams. Our clinical linguists are subject matter experts, our process builds in independent review and terminology control across every language, and our quality system is certified to ISO 9001, ISO 17100 and ISO 27001, and for suitable content, we pair custom neural machine translation with expert human review. 

If you’re adding countries to a trial, get in touch before your submission timeline is set, ideally with your country list and document list ready, and we can talk through your language plan. 

EXPERIENCE THE BIG DIFFERENCE TODAY

See how BIG Language Solutions
can work for your business.